MedPage Today: Encouraging data on treatment for certain stroke population
UC's Mistry comments on recent study in accompanying editorial
A recent study found that using clot-busting drugs in stroke patients who had recently ingested blood thinners did not raise the risk of bleeding complications.
The study found that patients who had taken a blood thinner (also known as a direct oral anticoagulant or DOAC) within 48 hours prior to being treated with clot-busting drugs had a lower incidence of symptomatic intracranial hemorrhage (sICH), the most-feared bleeding complication of stroke.
Eva Mistry, MBBS, wrote an accompanying editorial in JAMA following the publication of the study. MedPage Today highlighted the research and Mistry's editorial.
"Notwithstanding the small number of patients in each group, it is reassuring to see that rates of sICH were comparable among these selection strategies," said Mistry, assistant professor in the Department of Neurology and Rehabilitation medicine in UC’s College of Medicine and a UC Health physician.
"Despite the limitations of the study design and enrolled population, these data may be used by clinicians to make individualized decisions regarding thrombolysis among patients with recent DOAC use. Importantly, this study lays the foundation for prospective, well-powered studies that definitively determine the safety of thrombolysis in this population," Mistry continued.
Read the MedPage Today article.
Featured photo at top of brain courtesy of iStock.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.